• Free for qualified executives and consultants to industry

  • Receive quarterly issues of Area Development Magazine and special market report and directory issues


Luye Life Sciences Group Opens R&D Center in Woburn, Massachusetts

The Luye Life Sciences Group, a pharmaceutical company in China with its medical services sector, Luye Medical, headquartered in Singapore, opened its R&D Center, in the Boston suburb of Woburn, Massachusetts.

This global R&D facility, nine miles north of Boston, will collaborate with multiple business divisions of the Luye Life Sciences Group including Luye Pharma, Luye Medical, and Luye Diagnostics.

According to company officials, as an integral part of Luye Life Sciences Group's global R&D system, the newly-built Boston R&D Center will focus on international R&D collaboration.

In particular, joint efforts between Chinese and U.S. teams will accelerate the research and development of new drug candidates in key disease areas. The Boston R&D Center will act as an important center of excellence to internalize novel early-stage biopharmaceutical assets and disruptive drug delivery technologies.

"The opening of our Boston R&D Center marks another milestone in the Group's exploration of pharmaceuticals," said Dr. Youxin Li, Global R&D President of Luye Pharma Group. "Building on existing R&D platforms for the drug delivery system(DDS)and Mab biosimilars, Luye Pharma is moving towards next-generation biopharmaceutical products and intelligent drug products.”

“With Boston's leading position in the global biopharmaceutical industry, we look forward to laying a solid technical foundation through collaboration on new platforms and projects, to help ensure the sustainable pipeline development of Luye Life Sciences Group,” Dr. Li said.

Several biotechnology companies have already expressed their interest in working with the Boston R&D Center, tracking and analyzing a number of new early-stage drugs and technologies, company officials said. These projects will effectively promote and strengthen the R&D capabilities of Luye Life Sciences Group in key areas such as cancer, schizophrenia, depression, cardiovascular anomalies, and Parkinson's disease.

"R&D innovation is a core engine of our globalization strategy," said Rongbing Yang, President of Luye Pharma Group. "This Boston R&D Center allows us to further integrate our R&D resources across the world, speed up the introduction of new drugs to China, and bring our originally-developed drugs to overseas markets in order to benefit more patients worldwide."

According to Dianbo Liu, Chairman of Luye Life Sciences Group, the establishment of the Boston R&D Center is of great strategic importance. "Through this globalized platform, we look forward to building close connections with local universities, research institutes, the industry, and the financial sector," he said. "We believe these connections will allow us to seamlessly integrate our global R&D resources with those of new partners in order to streamline innovation and realize the commercialization of high-quality biopharmaceutical products.”

“We will continue to invest in this center, especially in terms of talent, capital, and operating processes. Ultimately, this will lead to the launch of many more innovative drugs as well as new products and technologies with real clinical value, thereby contributing to the health of all humankind,” Liu said.


Exclusive Research